433 related articles for article (PubMed ID: 34440488)
1. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
Cheng SL
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
[TBL] [Abstract][Full Text] [Related]
2. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
3. Biologics in severe asthma.
Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
[TBL] [Abstract][Full Text] [Related]
4. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
Ragnoli B; Morjaria J; Pignatti P; Montuschi P; Barbieri M; Mondini L; Ruggero L; Trotta L; Malerba M
Ther Adv Chronic Dis; 2022; 13():20406223221097327. PubMed ID: 35655942
[TBL] [Abstract][Full Text] [Related]
6. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
7. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
8. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
Mavissakalian M; Brady S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
[TBL] [Abstract][Full Text] [Related]
9. A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh JE; Hearn AP; Jackson DJ
Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
Pelaia C; Pelaia G; Longhini F; Crimi C; Calabrese C; Gallelli L; Sciacqua A; Vatrella A
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572294
[TBL] [Abstract][Full Text] [Related]
11. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Bel EH; Ten Brinke A
Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
[TBL] [Abstract][Full Text] [Related]
12. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
van Dijk YE; Rutjes NW; Golebski K; Şahin H; Hashimoto S; Maitland-van der Zee AH; Vijverberg SJH
Paediatr Drugs; 2023 Nov; 25(6):677-693. PubMed ID: 37658954
[TBL] [Abstract][Full Text] [Related]
13. Specific Therapy for T2 Asthma.
Bagnasco D; Testino E; Nicola S; Melissari L; Russo M; Canevari RF; Brussino L; Passalacqua G
J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455709
[TBL] [Abstract][Full Text] [Related]
14. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
15. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
18. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
Ohta K; Nagase H; Suzukawa M; Ohta S
Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
[TBL] [Abstract][Full Text] [Related]
19. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.
Chen CY; Wu KH; Guo BC; Lin WY; Chang YJ; Wei CW; Lin MJ; Wu HP
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203353
[TBL] [Abstract][Full Text] [Related]
20. Novel Biological Therapies in Severe Asthma: Targeting the Right Trait.
Varricchi G; Marone G; Spadaro G; Russo M; Granata F; Genovese A; Marone G
Curr Med Chem; 2019; 26(16):2801-2822. PubMed ID: 29318959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]